Telefon:
+49 (0)241 95 163 153
Fax:
+49 (0)241 95 163 155
E-Mail:
orders@antikoerper-online.de

APOA1 Antikörper

Es gibt 1 Publikation für dieses Produkt. Der Ziege Polyklonal anti-APOA1 Antikörper wird verwendet zum Nachweis von APOA1 in Proben von Human. Er wurde validiert für WB, IP, IHC (p), EIA und IHC (fro).
Produktnummer ABIN116540
2.710,77 €
Zzgl. Versandkosten 20,00 € und MwSt
1 mg
Lieferung nach: Deutschland
Lieferung in 16 Werktagen

Kurzübersicht für APOA1 Antikörper (ABIN116540)

Target

Alle APOA1 Antikörper anzeigen
APOA1 (Apolipoprotein A-I (APOA1))

Reaktivität

  • 123
  • 46
  • 24
  • 12
  • 12
  • 12
  • 4
  • 3
  • 2
  • 1
  • 1
  • 1
Human

Wirt

  • 102
  • 54
  • 19
  • 6
  • 3
  • 3
  • 2
Ziege

Klonalität

  • 119
  • 69
Polyklonal

Konjugat

  • 96
  • 34
  • 14
  • 10
  • 8
  • 3
  • 3
  • 3
  • 3
  • 3
  • 3
  • 3
  • 2
  • 2
  • 1
  • 1
Dieser APOA1 Antikörper ist unkonjugiert

Applikation

  • 131
  • 75
  • 71
  • 42
  • 40
  • 17
  • 14
  • 12
  • 8
  • 8
  • 5
  • 5
  • 4
  • 2
  • 1
  • 1
  • 1
  • 1
  • 1
  • 1
  • 1
  • 1
  • 1
  • 1
Western Blotting (WB), Immunoprecipitation (IP), Immunohistochemistry (Paraffin-embedded Sections) (IHC (p)), Enzyme Immunoassay (EIA), Immunohistochemistry (Frozen Sections) (IHC (fro))
  • Spezifität

    Typically less than 1 % cross reactivity against other types of Apolipoprotein was detected by ELISA against purified standards. This antibody reacts with Human Apolipoprotein A-I and has negligible cross-reactivity with Type A-II, B, C-I, C-II, C-III, E and J Apolipoproteins. Non-specific cross reaction of anti-Apolipoprotein antibodies with other Human serum proteins is negligible.

    Kreuzreaktivität (Details)

    Species reactivity (tested):Human.

    Aufreinigung

    Immunoaffinity Chromatography using immobilized antigens followed by extensive cross-adsorption against other Apolipoproteins and human serum proteins to remove any unwanted specificities.

    Immunogen

    Apolipoprotein Type A-I was isolated from Human plasma by density gradient centrifugation followed by HPLC purification.
  • Applikationshinweise

    Anti-Apolipoprotein antibodies have been used for Indirect trapping ELISA for quantitationof antigen in serum using a standard curve, for Immunoprecipitation and for Westernblotting for highly sensitive qualitative analysis. Recommended dilutions: ELISA: 1/10,000-1/20,000. Western blot: 1/5,000-1/10,000. Immunoprecipitation: 1/100. Immunohistochemistry: 1/50-1/200.

    Beschränkungen

    Nur für Forschungszwecke einsetzbar
  • Konzentration

    1.0 mg/mL (by UV absorbance at 280 nm)

    Buffer

    0.125 M Sodium Borate, 0.075 M Sodium Chloride, 0.005 M EDTA, pH 8.0, 0.01 % Sodium Azide, None

    Konservierungsmittel

    Sodium azide

    Vorsichtsmaßnahmen

    This product contains sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

    Handhabung

    Dilute only prior to immediate use. Avoid cycles of freezing and thawing.

    Lagerung

    -20 °C

    Informationen zur Lagerung

    Store vial at -20 °C prior to opening. Centrifuge product if not completely clear after standing at room temperature. For extended storage aliquot contents and freeze at -20 °C or below.
  • Bernthaler, Epping, Schmitz, Deplazes, Brehm: "Molecular characterization of EmABP, an apolipoprotein A-I binding protein secreted by the Echinococcus multilocularis metacestode." in: Infection and immunity, Vol. 77, Issue 12, pp. 5564-71, (2009) (PubMed).

  • Target

    APOA1 (Apolipoprotein A-I (APOA1))

    Andere Bezeichnung

    Apolipoprotein A I (APO AI)

    Hintergrund

    Apolipoprotein A I promotes cholesterol efflux from tissues to the liver for excretion. Apolipoprotein A I is the major protein component of high density lipoprotein (HDL) in the plasma. Synthesized in the liver and small intestine, it consists of two identical chains of 77 amino acids, an 18 amino acid signal peptide is removed co-translationally and a 6 amino acid propeptide is cleaved post-translationally. Apolipoprotein A I is a cofactor for lecithin cholesterolacyltransferase (LCAT) which is responsible for the formation of most plasma cholesteryl esters. Defects in the Apolipoprotein A I gene are associated with HDL deficiency and Tangier disease. The therapeutic potential of apoA-I has been recently assessed in patients with acute coronary syndromes, using a recombinant form of a naturally occurring variant of apoA-I. The availability of recombinant normal apoA-I should facilitate further investigation into the potential usefulness of apoA-I in preventing atherosclerotic vascular diseases.Synonyms: APOA1, Apo-AI, ApoA-I, ApoAI

    Gen-ID

    335

    NCBI Accession

    NP_000030

    UniProt

    P02647

    Pathways

    Regulation of Lipid Metabolism by PPARalpha, Production of Molecular Mediator of Immune Response, Lipid Metabolism
Sie sind hier:
Chat with us!